MedPath

pilot study of systemic combination therapy with TS-1 and IFN for hepatocellular carcinoma patients with extrahepatic metastases who do not response to systemic combination therapy with TS-1 and cisplatin.

Not Applicable
Conditions
hepatocellular carcinoma with extrahepatic metastases
Registration Number
JPRN-UMIN000002929
Lead Sponsor
Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical, Hiroshima University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
10
Inclusion Criteria

Not provided

Exclusion Criteria

1) With other malignant disease. 2) A pregnant woman, or a woman suspected of pregnancy. 3) With severe infectious disease. 4) With history of severe allergy. 5) With severe renal function disease. 6) With severe allergy for 5FU, TS-1 or IFN. 7) With severe bone marrow supression. 8) With pulmonary fibrosis. 9) With another fluoropyrimidine 10)With flucytosine 9) with shosaikoto 10) with autoimmune hepatitis

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
response rate
Secondary Outcome Measures
NameTimeMethod
1) overall survival 2) time to progression 3) safety
© Copyright 2025. All Rights Reserved by MedPath